查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048324

口腔乾燥症治療市場－全球產業規模、佔有率、趨勢、機會與預測：按類型、產品、地區和競爭格局分類，2021-2031年

Xerostomia Therapeutics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type (OTC, Prescription), By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 192 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球口乾症治療市場預計將從 2025 年的 27.4 億美元成長到 2031 年的 34.7 億美元，複合年成長率為 4.02%。

這些治療方法包括藥物和人工唾液替代品，旨在透過促進自然唾液分泌或模擬口腔濕潤環境來緩解口乾症的症狀。市場促進因素包括老年人口的成長以及自體免疫疾病和頭頸癌等慢性疾病發生率的上升。這是因為這些疾病的治療通常需要使用會損害唾液腺功能的治療方法。例如，美國癌症協會估計，到2025年，美國將新增約59,660例口腔癌和口咽癌病例，預計將直接增加對治療方法放射療法引起的唾液功能障礙的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 27.4億美元
市場規模：2031年 34.7億美元
複合年成長率：2026-2031年 4.02%
成長最快的細分市場 牙膏
最大的市場 北美洲

然而，市場成長的一大障礙是長期治療口乾症帶來的沉重經濟負擔。許多先進的處方藥和酵素療法對於缺乏足夠醫療保險的患者來說價格極為昂貴。這種經濟障礙嚴重限制了現有治療方法的廣泛應用和持續使用，尤其是在醫療預算往往有限的開發中國家。

市場促進因素

口乾症（口腔乾燥）治療市場的主要驅動力是全球老年人口的快速成長。隨著老齡化，由於唾液腺的自然退化性變化，唾液功能會顯著受損，而老齡化本身就與腺泡萎縮和唾液分泌減少密切相關。這使得人們對緩解症狀的治療和唾液替代品的需求持續成長，以維持口腔健康。這種人口趨勢必然會導致需要長期治療性介入而非短期急性照護的患者群體不斷擴大。正如世界衛生組織（WHO）在其2025年10月發布的《老化與健康》概況介紹中所述，預計到2050年，全球60歲及以上人口將加倍，達到21億，這凸顯了製造商正致力於研發適合該老齡化配方的重要目標人群。

同時，已知會引起口乾的藥物被廣泛使用，顯著推動了市場成長，尤其是在多種藥物聯合用於治療慢性疾病的情況下。口乾是許多重要藥物類別的常見副作用，包括降血壓藥、抗憂鬱症和抗組織胺藥，迫使患者依賴非處方藥來緩解症狀。 Oralieve 於 2025 年 2 月進行的一項調查發現，超過 70% 的醫療保健專業人員認為藥物副作用和多重用藥是患者口乾的主要原因。這種直接的因果關係為專業口腔護理品牌帶來了巨大的商機。根據 Haleon 於 2025 年 3 月發布的 2024 年年度報告和 20-F 表格，該公司口腔健康部門的銷售額達到 33 億英鎊，成長 5.6%。這一成長部分歸功於針對口腔健康惡化的創新治療產品。

市場挑戰

由於治療費用高且健保覆蓋不足，全球口乾症治療市場面臨嚴峻挑戰。儘管先進的藥物和酶基唾液替代品價格昂貴，但許多公共和私人醫療保險計劃將這些產品歸類為非必需或僅作為輔助治療。這種報銷差異迫使患者自掏腰包承擔大量費用。因此，許多患者，尤其是低收入患者或居住在發展中地區的患者，被迫選擇價格更低但療效較差的非處方藥，甚至完全停止治療，這反過來又降低了產品銷量，阻礙了市場滲透。

這種經濟障礙的影響尤其嚴重，因為它主要影響老年人，而老年人正是口乾症藥物的主要消費群體。當這一核心群體因經濟拮据而無法獲得必要的治療時，市場的收入成長潛力便會直接下降。根據美國牙科保險協會（National Association of Dental Plans）預測，到2025年，只有約70%的老年人擁有牙科保險。如此嚴重的保險覆蓋不足意味著，很大一部分最弱勢群體將不得不完全自費支付治療費用，這反過來又會阻礙處方箋級口乾症藥物的普及，並直接抑制整個市場的成長趨勢。

市場趨勢

治療口乾症的關鍵趨勢之一是再生醫學和基因療法的出現，這標誌著治療策略正從單純緩解症狀轉向根治性恢復唾液功能。與只能提供暫時緩解的傳統唾液腺促效劑不同，這些創新的生物療法旨在修復受輻射損傷的唾液腺組織或糾正基因缺陷，從而永久恢復人體自然的唾液分泌。這一趨勢在臨床開發中進展迅速，製藥公司正積極尋求在頭頸癌患者中實現長期療效。例如，MeiraGTx在2025年11月發布的「2025年第三季財務業績」中報告稱，其用於治療輻射誘發唾液腺收縮障礙的基因療法AAV-hAQP1的主要II期臨床試驗已完成最終隊列的招募，並預計將於2027年核准生技藥品上市申請。

同時，經臨床驗證的非處方藥產品線不斷擴展，正在改變市場格局，製造商也越來越重視科學證據，以凸顯其標準化口腔清潔用品解決方案的差異化優勢。主要市場參與者正增加對專業研發基礎設施的投入，以開發具有卓越生物黏附性和持久保濕效果的先進產品，從而有效縮小消費品與處方箋級治療方法之間的差距。這種全產業加強研發能力的努力也體現在近期旨在加速產品創新的大規模資本投資。正如Haleon在2025年7月發布的新聞稿《Haleon啟動全球口腔健康研發中心建設》中所詳述，該公司已在英國啟動一座耗資1.3億英鎊的設施建設。該設施旨在成為下一代口腔健康技術研發和新型治療方案商業化的全球中心。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球口乾症治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（非處方藥、處方藥）
    • 依產品類型（唾液分泌促效劑、唾液替代品、牙膏）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美口乾症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲口乾症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區口乾症治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲口乾症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲口乾症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球口乾症治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • GlaxoSmithKline plc
  • Church & Dwight Co., Inc.
  • Colgate-Palmolive Company
  • Hikma Pharmaceuticals PLC
  • Pharmascience Inc.
  • Sun Pharmaceuticals Industries Ltd
  • Lupin Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Parnell Pharmaceuticals, Inc.
  • Acacia Pharma

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16619

The Global Xerostomia Therapeutics Market is projected to expand from USD 2.74 Billion in 2025 to USD 3.47 Billion by 2031, exhibiting a Compound Annual Growth Rate (CAGR) of 4.02%. These therapeutics involve pharmaceutical drugs and artificial saliva substitutes intended to relieve dry mouth symptoms by encouraging natural saliva production or replicating oral moisture. Key market drivers include the growing elderly demographic and the increasing incidence of chronic illnesses such as autoimmune disorders and head and neck cancers, which often require treatments that impair salivary gland function. For instance, the American Cancer Society estimated around 59,660 new cases of oral or oropharyngeal cancer in the U.S. in 2025, directly boosting demand for therapies to address salivary dysfunction caused by radiation.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.74 Billion
Market Size 2031USD 3.47 Billion
CAGR 2026-20314.02%
Fastest Growing SegmentDentifrices
Largest MarketNorth America

However, a substantial impediment to market growth is the significant financial strain associated with long-term xerostomia management. Many advanced prescription medications and enzymatic substitutes are exceptionally costly for patients without adequate insurance. This financial barrier severely restricts the broad uptake and consistent use of available therapeutic options, particularly in developing countries where healthcare spending is often limited.

Market Driver

The primary impetus driving the xerostomia therapeutics market is the rapidly increasing global geriatric population. As individuals age, natural degeneration of salivary glands substantially impairs salivary function, with aging being inherently linked to acinar atrophy and diminished salivary flow. This creates a persistent need for palliative treatments and salivary substitutes to maintain oral health. This demographic trend guarantees an expanding patient cohort requiring long-term therapeutic interventions rather than short-term acute care. The World Health Organization (WHO) projects that the global population aged 60 and above will double to 2.1 billion by 2050, as stated in its October 2025 'Ageing and Health' fact sheet, underscoring the significant demographic manufacturers aim to serve with age-appropriate formulations.

Simultaneously, the widespread prescription of medications known to cause xerostomia significantly boosts market expansion, particularly where multiple drugs are used for chronic disease management. Numerous critical drug categories, such as antihypertensives, antidepressants, and antihistamines, frequently list dry mouth as a common side effect, compelling patients to seek over-the-counter remedies for relief. An Oralieve survey from February 2025 indicated that over 70% of healthcare professionals identified medication side effects and polypharmacy as leading causes of dry mouth among their patients. This direct causal link generates substantial commercial prospects for specialized oral care brands; Haleon's Annual Report and Form 20-F 2024, published in March 2025, reported their Oral Health category revenue reaching £3.3 billion, a 5.6% increase partly attributed to innovative therapeutic products addressing compromised oral conditions.

Market Challenge

The Global Xerostomia Therapeutics Market faces a substantial challenge due to the high cost of treatment coupled with inadequate comprehensive insurance coverage. Sophisticated pharmacological agents and enzymatic saliva substitutes frequently carry premium price tags, yet a considerable number of public and private insurance policies categorize these products as non-essential or merely supportive care. This gap in reimbursement mandates patients to incur significant financial costs through out-of-pocket payments. As a result, many individuals, especially those with limited incomes or residing in developing areas, are forced to choose more affordable, less effective over-the-counter options, or even cease treatment altogether, which subsequently reduces product sales volumes and impedes market penetration.

This economic obstacle is particularly damaging because it predominantly affects the geriatric population, which forms the primary consumer segment for xerostomia therapeutics. When the core demographic encounters restricted access to necessary care due to financial constraints, the market's potential for revenue growth is directly diminished. In 2025, only about 70% of seniors had dental coverage, according to the National Association of Dental Plans. This significant coverage shortfall leaves a large segment of the most susceptible population responsible for the full cost of treatment, thus discouraging the adoption of prescription-grade xerostomia therapies and directly stifling the market's overall expansion trajectory.

Market Trends

A significant trend in xerostomia therapeutics is the emergence of regenerative medicine and gene therapy candidates, indicating a foundational shift from mere palliative symptom relief to the curative restoration of salivary function. In contrast to conventional sialagogues that offer only temporary alleviation, these innovative biotherapeutic approaches aim to repair salivary gland tissues damaged by radiation or to correct genetic deficiencies, thereby permanently re-establishing the body's natural saliva production. This trend is progressing swiftly through clinical development, with pharmaceutical companies actively pursuing long-term effectiveness for patients afflicted by head and neck cancers. For instance, MeiraGTx, in its November 2025 'Third Quarter 2025 Financial and Operational Results', reported enrolling the final cohorts for its pivotal Phase 2 study of AAV-hAQP1, a gene therapy for radiation-induced xerostomia, with a biologics license application filing anticipated in 2027.

Concurrently, the proliferation of clinically validated over-the-counter product lines is transforming the market as manufacturers increasingly emphasize scientific evidence to distinguish their standardized oral care solutions. Leading market players are dedicating more resources to specialized research infrastructure to formulate advanced products that deliver superior bio-adhesion and extended moisture retention, effectively narrowing the gap between basic consumer products and prescription-level therapies. This sector-wide dedication to enhancing research and development capabilities is evident in recent major capital investments aimed at accelerating product innovation. As detailed in Haleon's July 2025 press release 'Haleon Breaks Ground on new Global Oral Health Innovation Centre', the company commenced construction on a £130 million facility in the UK, designed to function as a global center for developing next-generation oral health technologies and commercializing novel therapeutic solutions.

Key Market Players

  • GlaxoSmithKline plc
  • Church & Dwight Co., Inc.
  • Colgate-Palmolive Company
  • Hikma Pharmaceuticals PLC
  • Pharmascience Inc.
  • Sun Pharmaceuticals Industries Ltd
  • Lupin Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Parnell Pharmaceuticals, Inc.
  • Acacia Pharma

Report Scope

In this report, the Global Xerostomia Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Xerostomia Therapeutics Market, By Type

  • OTC
  • Prescription

Xerostomia Therapeutics Market, By Product

  • Salivary Stimulants
  • Salivary Substitutes
  • Dentifrices

Xerostomia Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Xerostomia Therapeutics Market.

Available Customizations:

Global Xerostomia Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Xerostomia Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (OTC, Prescription)
    • 5.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Xerostomia Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Product
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Xerostomia Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Product
    • 6.3.2. Canada Xerostomia Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Product
    • 6.3.3. Mexico Xerostomia Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Product

7. Europe Xerostomia Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Product
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Xerostomia Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Product
    • 7.3.2. France Xerostomia Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Product
    • 7.3.3. United Kingdom Xerostomia Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Product
    • 7.3.4. Italy Xerostomia Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Product
    • 7.3.5. Spain Xerostomia Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Product

8. Asia Pacific Xerostomia Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Product
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Xerostomia Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Product
    • 8.3.2. India Xerostomia Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Product
    • 8.3.3. Japan Xerostomia Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Product
    • 8.3.4. South Korea Xerostomia Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Product
    • 8.3.5. Australia Xerostomia Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Product

9. Middle East & Africa Xerostomia Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Product
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Xerostomia Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Product
    • 9.3.2. UAE Xerostomia Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Product
    • 9.3.3. South Africa Xerostomia Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Product

10. South America Xerostomia Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Product
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Xerostomia Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Product
    • 10.3.2. Colombia Xerostomia Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Product
    • 10.3.3. Argentina Xerostomia Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Product

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Xerostomia Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. GlaxoSmithKline plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Church & Dwight Co., Inc.
  • 15.3. Colgate-Palmolive Company
  • 15.4. Hikma Pharmaceuticals PLC
  • 15.5. Pharmascience Inc.
  • 15.6. Sun Pharmaceuticals Industries Ltd
  • 15.7. Lupin Pharmaceuticals, Inc.
  • 15.8. Pfizer, Inc.
  • 15.9. Parnell Pharmaceuticals, Inc.
  • 15.10. Acacia Pharma

16. Strategic Recommendations

17. About Us & Disclaimer